Leap Therapeutics Inc logo

Leap Therapeutics Inc

$ 0.92 +0.0201 (+2.24%) 04:00 PM EST
P/E:
At Loss
P/B:
0.96
Market Cap:
$ 90.90M
Enterprise V:
$ -1.10M
Volume:
727.13K
Avg Vol (2M):
702.14K
Also Trade In:
Volume:
727.13K
Market Cap $:
90.90M
PE Ratio:
At Loss
Avg Vol (2-Month):
702.14K
Enterprise Value $:
-1.10M
PB Ratio:
0.96
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.
Name Current Vs Industry Vs History
Cash-To-Debt 104.58
Equity-to-Asset 0.88
Debt-to-Equity 0.01
Debt-to-EBITDA -0.02
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.46
Distress
Grey
Safe
Beneish M-Score 64.71
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 30.75
9-Day RSI 30.53
14-Day RSI 34.71
6-1 Month Momentum % -19.02
12-1 Month Momentum % -59.18

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.88
Quick Ratio 8.88
Cash Ratio 8.73

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -81.8
Name Current Vs Industry Vs History
Operating Margin % -6483.33
Net Margin % -6576.93
ROE % -56.51
ROA % -50.95
ROIC % -2087.45
ROC (Joel Greenblatt) % -9805.49
ROCE % -56.41

Financials (Next Earnings Date:2022-11-11 Est.)

LPTX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:LPTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.75
EPS (TTM) ($) -0.48
Beta -0.01
Volatility % 82.13
14-Day RSI 34.71
14-Day ATR ($) 0.110948
20-Day SMA ($) 1.15617
12-1 Month Momentum % -59.18
52-Week Range ($) 0.85 - 3.77
Shares Outstanding (Mil) 99.02

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Leap Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Leap Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.